AVEO Oncology (AVEO) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
AVEO Oncology Reports First Quarter 2022 Financial Results
May 5, 2022 7:00 AM EDTTotal Q1 2022 Net Revenue of $20.9 Million including $20.1 Million ofFOTIVDA® (tivozanib) U.S. Net Product Revenue
Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021
Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million
Company to Host Conference Call Today at 8:30 a.m. ET
BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial... More



